Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Aliaksandr Prokharau"'
Autor:
Dilyara Kaidarova, Edvard Zhavrid, Oxana Shatkovskaya, Aliaksandr Prokharau, Nina Akhmed, Dauren Sembayev, Zhanna Rutzhanova, Alexandr Ivankov
Publikováno v:
Cancer Treatment and Research Communications, Vol 40, Iss , Pp 100817- (2024)
Aim: To assess the safety and tolerability of subcutaneous (SC) trastuzumab (Herceptin) administered either with a single-use injection device (SID) or manually from a vial using a hand-held syringe. Methods: The ESCAPE trial (NCT02194166) included 9
Externí odkaz:
https://doaj.org/article/9bfed06629a640149cf386d3975e418f
Autor:
KeumYoung Ahn, Mariana Vasilica, Christian Buske, Rajnish Nagarkar, Edvard Zhavrid, Aliaksandr Prokharau, Sung-Hyun Kim, Juan-Manuel Sancho, Michinori Ogura, Won Seog Kim, Wojciech Jurczak, Jose Angel Hernandez-Rivas, Jin Seok Kim, Sang Joon Lee, Larry W. Kwak
Publikováno v:
Blood Adv
Rituximab biosimilars are a cornerstone of treatment of advanced-stage follicular lymphoma (FL). This double-blind, parallel-group, phase 3 trial randomized (1:1) adults (≥18 years) with stage III to IV indolent B-cell lymphoma, including grades 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::570156d56cfdcfb078330f5d56b56710
https://doi.org/10.1182/bloodadvances.2021004484
https://doi.org/10.1182/bloodadvances.2021004484
Autor:
Catherine Leger, Toshihiko Doi, Kazuhiro Nishikawa, Aliaksandr Prokharau, Suayib Yalcin, David H. Ilson, C. Faustino, Takayuki Ando, Vera Gorbunova, Wasat Mansoor, Kohei Shitara, Donia Skanji, Javier Sabater, Nadia Amellal, Michele Ghidini, Eric Van Cutsem, Maria Alsina, Edvard Zhavrid, Josep Tabernero, Mikhail Dvorkin, Hendrik-Tobias Arkenau
Publikováno v:
Scientia
Gastric Cancer
Gastric Cancer
Background In TAGS, an international, double-blind, phase 3 trial, trifluridine/tipiracil significantly improved overall survival and progression-free survival compared with placebo in heavily pretreated metastatic gastric cancer patients. This paper
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f279f17b20c298de80ea1c7855af538f
https://doi.org/10.1007/s10120-020-01053-9
https://doi.org/10.1007/s10120-020-01053-9
Autor:
Kazumasa Fujitani, Daniel V.T. Catenacci, Edvard Zhavrid, Kohei Shitara, Hendrik-Tobias Arkenau, Ben George, Michele Ghidini, Wasat Mansoor, Eric Van Cutsem, Maria Alsina, Peter C. Thuss-Patience, Toshihiko Doi, Aliaksandr Prokharau, Lukas Makris, Giordano D. Beretta, Sandra McGuigan, David H. Ilson, Josep Tabernero
IMPORTANCE: Trifluridine/tipiracil (FTD/TPI) treatment has shown clinical benefit in patients with pretreated metastatic gastric cancer or gastroesophageal junction cancer (mGC/GEJC). Patients who have undergone gastrectomy constitute a significant p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38d882f2f24a79d9a88001b8f6d121d0
https://lirias.kuleuven.be/handle/123456789/642817
https://lirias.kuleuven.be/handle/123456789/642817
Autor:
Vera Gorbunova, Giordano D. Beretta, Kazuhiro Nishikawa, Hendrik-Tobias Arkenau, Maria Alsina, Kohei Shitara, M Dvorkin, Aliaksandr Prokharau, Suayib Yalcin, Kazumasa Fujitani, Josep Tabernero, Robert Winkler, Lukas Makris, Eric Van Cutsem, Wasat Mansoor, Michele Ghidini, C. Faustino, Edvard Zhavrid, Ayumu Hosokawa, David H. Ilson, Toshihiko Doi
Publikováno v:
The Lancet Oncology. 19:1437-1448
Summary Background Trifluridine/tipiracil showed activity and was well tolerated in a phase 2 study of pretreated patients with advanced gastric cancer done in Japan. We investigated whether the treatment was efficacious compared with placebo in a gl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef456724893503a88f7d68fb177a5053
https://doi.org/10.1016/s1470-2045(18)30739-3
https://doi.org/10.1016/s1470-2045(18)30739-3
Autor:
Jin Seok Kim, Michinori Ogura, Dzhelil Osmanov, Mariana Vasilica, Christian Buske, Sang Joon Lee, Edvard Zhavrid, Rajinish Nagarkar, Yun Ju Bae, Won Seog Kim, Wojciech Jurczak, Jose Angel Hernandez-Rivas, Sungyoung Lee, Bertrand Coiffier, Aliaksandr Prokharau, Juan-Manuel Sancho, Larry W. Kwak
Publikováno v:
Lancet Haematology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Background Studies in patients with rheumatoid arthritis have shown that the rituximab biosimilar CT-P10 (Celltrion, Incheon, South Korea) has equivalent efficacy and pharmacokinetics to rituximab. In this phase 3 study, we aimed to assess the non-in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a154b2d3cedc796daf82baa5e082611
https://pubmed.ncbi.nlm.nih.gov/28754191
https://pubmed.ncbi.nlm.nih.gov/28754191
Autor:
Michinori Ogura, Keum Young Ahn, Mariana Vasilica, Christian Buske, Aliaksandr Prokharau, Larry W. Kwak, Jin Seok Kim, Rajnish Nagarkar, Juan-Manuel Sancho, Won Seog Kim, Edvard Zhavrid, Sang-Joon Lee, Wojciech Jurczak, Jose Angel Hernandez-Rivas, Gayane Tumyan, Sung-Hyun Kim
Publikováno v:
Blood. 134:1528-1528
Introduction : CT-P10 is an approved biosimilar to the innovator rituximab by both US FDA and EMA based on a review of comprehensive data package inclusive of foundational and extensive analytical characterization, nonclinical and clinical data. In p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e874df0e8bbc367dd254fb4f8bc0b812
https://doi.org/10.1182/blood-2019-126379
https://doi.org/10.1182/blood-2019-126379
Autor:
Mikhail Dvorkin, Kohei Shitara, Donia Skanji, Aliaksandr Prokharau, Hendrik-Tobias Arkenau, Javier Sabater, Josep Tabernero, David H. Ilson, Edvard Zhavrid, Maria Alsina, Catherine Leger, Takayuki Ando, C. Faustino, Wasat Mansoor, Vera Gorbunova, Kazuhiro Nishikawa, Michele Ghidini, Toshihiko Doi, Eric Van Cutsem, Suayib Yalcin
Publikováno v:
Journal of Clinical Oncology. 37:4043-4043
4043 Background: The phase 3, randomized, double-blind, placebo-controlled study (TAGS) evaluated the efficacy and safety of FTD/TPI (35 mg/m² given orally twice a day on days 1–5 and 8–12 of a 28-day cycle) in mGC patients who had previously re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6bf54817423c22430e35f040779e0ede
https://doi.org/10.1200/jco.2019.37.15_suppl.4043
https://doi.org/10.1200/jco.2019.37.15_suppl.4043
Autor:
Michele Ghidini, Peter C. Thuss-Patience, Kohei Shitara, Daniel V.T. Catenacci, Kazumasa Fujitani, Eric Van Cutsem, Lukas Makris, Robert Winkler, Hendrik-Tobias Arkenau, Ben George, Aliaksandr Prokharau, Wasat Mansoor, Maria Alsina, David H. Ilson, Toshihiko Doi, Giordano D. Beretta, Edvard Zhavrid
Publikováno v:
Journal of Clinical Oncology. 37:3-3
3 Background: The phase 3 study TAGS demonstrated that the novel oral therapy FTD/TPI (TAS-102) represents an effective treatment option with a manageable safety profile for pts with heavily pretreated mGC. In an earlier single-arm Japanese phase 2 t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1384626a258734f2d2f27b8c2786f956
https://doi.org/10.1200/jco.2019.37.4_suppl.3
https://doi.org/10.1200/jco.2019.37.4_suppl.3
Autor:
Bertrand Coiffier, Dzhelil Osmanov, Mariana Vasilica, Won Seog Kim, Aliaksandr Prokharau, Sungyoung Lee, Juan-Manuel Sancho, Christian Buske, Jin Seok Kim, Sang-Joon Lee, Wojciech Jurczak, Edvard Javrid, Larry W. Kwak, Rajnish Nagarkar, Jose Angel Hernandez Rivas, Michinori Ogura, Yunju Bae
Publikováno v:
Journal of Clinical Oncology. 35:7532-7532
7532 Background: CT-P10 is a biosimilar candidate to the innovator rituximab (RTX). In patients with rheumatoid arthritis, CT-P10 has demonstrated equivalence in pharmacokinetics (PK) and efficacy (Yoo, ACR 2016). This study aimed to demonstrate non-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ffd8005855349eb41eafae3d640c153e
https://doi.org/10.1200/jco.2017.35.15_suppl.7532
https://doi.org/10.1200/jco.2017.35.15_suppl.7532